Stock Market

UBS Maintains Neutral Stance on Jasper Therapeutics Despite Briquilimab Progress

By Bullbit Editorial · March 29, 2026

WhatUBS initiated coverage on Jasper Therapeutics with a neutral rating
WhyDespite progress in Briquilimab, UBS cites concerns over the company's valuation
SignalUBS sees potential in Jasper Therapeutics' pipeline, but requires more data
TargetUBS sets a price target of $**15.00** for Jasper Therapeutics shares
RiskValuation risks and clinical trial outcomes pose significant risks to the company's stock